Samsung Bioepis
E850006
Samsung Bioepis is a South Korean biopharmaceutical company specializing in the development and commercialization of biosimilar medicines.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Samsung Bioepis canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10214622 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Samsung Bioepis Context triple: [Renflexis, isManufacturedBy, Samsung Bioepis]
-
A.
Samsung Biologics
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
B.
Biolon
Biolon is a tributary stream that feeds into Lake Annecy in southeastern France.
-
C.
Ventris
Ventris is the surname of Michael Ventris, the British architect and linguist renowned for deciphering the ancient script Linear B.
-
D.
Organix
Organix is the first studio album by hip hop band The Roots, showcasing their early jazz-influenced, live-instrument approach to rap music.
-
E.
Efficeon
Efficeon is a family of low-power, x86-compatible microprocessors developed by Transmeta as the successor to its Crusoe line, aimed primarily at mobile and embedded computing devices.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Samsung Bioepis Target entity description: Samsung Bioepis is a South Korean biopharmaceutical company specializing in the development and commercialization of biosimilar medicines.
-
A.
Samsung Biologics
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
B.
Biolon
Biolon is a tributary stream that feeds into Lake Annecy in southeastern France.
-
C.
Ventris
Ventris is the surname of Michael Ventris, the British architect and linguist renowned for deciphering the ancient script Linear B.
-
D.
Organix
Organix is the first studio album by hip hop band The Roots, showcasing their early jazz-influenced, live-instrument approach to rap music.
-
E.
Efficeon
Efficeon is a family of low-power, x86-compatible microprocessors developed by Transmeta as the successor to its Crusoe line, aimed primarily at mobile and embedded computing devices.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
biosimilar manufacturer ⓘ |
| businessModel |
commercialization of biosimilars
ⓘ
development of biosimilars ⓘ |
| collaboratesWith |
Biogen
NERFINISHED
ⓘ
Biogen Idec NERFINISHED ⓘ Merck & Co. NERFINISHED ⓘ Organon NERFINISHED ⓘ |
| country | South Korea ⓘ |
| focusesOn |
diabetes
ⓘ
immunology ⓘ oncology ⓘ ophthalmology ⓘ |
| followsRegulatoryGuidelinesOf |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| foundedAsJointVentureWith | Biogen NERFINISHED ⓘ |
| hasOfficialWebsite | https://www.samsungbioepis.com ⓘ |
| hasProduct |
Amelivu
NERFINISHED
ⓘ
Aybintio NERFINISHED ⓘ Benepali NERFINISHED ⓘ Flixabi NERFINISHED ⓘ Hadlima NERFINISHED ⓘ Imraldi NERFINISHED ⓘ Ontruzant NERFINISHED ⓘ Renflexis NERFINISHED ⓘ |
| hasProductType |
adalimumab biosimilar
ⓘ
bevacizumab biosimilar ⓘ etanercept biosimilar ⓘ infliximab biosimilar ⓘ insulin glargine biosimilar ⓘ trastuzumab biosimilar ⓘ |
| hasResearchAndDevelopmentCenterIn | Incheon GENERATED ⓘ |
| headquartersLocation |
Incheon
NERFINISHED
ⓘ
Songdo International Business District NERFINISHED ⓘ |
| industry |
biopharmaceutical
ⓘ
biotechnology ⓘ pharmaceutical ⓘ |
| languageOfName | Korean ⓘ |
| parentOrganization |
Samsung Biologics
NERFINISHED
ⓘ
Samsung Group NERFINISHED ⓘ |
| partOf | Samsung Life Science business NERFINISHED ⓘ |
| regulatoryApprovalIn |
Australia
NERFINISHED
ⓘ
Canada NERFINISHED ⓘ European Union NERFINISHED ⓘ South Korea NERFINISHED ⓘ United States NERFINISHED ⓘ |
| specializesIn |
biologic medicines
ⓘ
biosimilars ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Samsung Bioepis Description of subject: Samsung Bioepis is a South Korean biopharmaceutical company specializing in the development and commercialization of biosimilar medicines.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.